Resistance to taxanes in triple-negative breast cancer associates with the dynamics of a CD49f+ tumor-initiating population J Gómez-Miragaya, M Palafox, L Paré, G Yoldi, I Ferrer, S Vila, P Galván, ... Stem cell reports 8 (5), 1392-1407, 2017 | 78 | 2017 |
RANK signaling blockade reduces breast cancer recurrence by inducing tumor cell differentiation G Yoldi, P Pellegrini, EM Trinidad, A Cordero, J Gomez-Miragaya, ... Cancer research 76 (19), 5857-5869, 2016 | 64 | 2016 |
Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs A Blancafort, A Giró-Perafita, G Oliveras, S Palomeras, C Turrado, ... PLoS One 10 (6), e0131241, 2015 | 62 | 2015 |
Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer L Piqué, A Martinez de Paz, D Piñeyro, A Martínez-Cardús, ... Oncogene 38 (45), 7106-7112, 2019 | 55 | 2019 |
Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition F Mateo, EJ Arenas, H Aguilar, J Serra-Musach, GR De Garibay, J Boni, ... Oncogene 36 (19), 2737-2749, 2017 | 41 | 2017 |
The altered transcriptome and DNA methylation profiles of docetaxel resistance in breast cancer PDX models J Gómez-Miragaya, S Moran, ME Calleja-Cervantes, A Collado-Sole, ... Molecular Cancer Research 17 (10), 2063-2076, 2019 | 22 | 2019 |
Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity J Gomez-Miragaya, A Diaz-Navarro, R Tonda, S Beltran, L Palomero, ... Cancer research 79 (16), 4258-4270, 2019 | 22 | 2019 |
Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer J Gomez-Miragaya, E González-Suárez Molecular & Cellular Oncology 4 (4), e1338208, 2017 | 15 | 2017 |
RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer A Sanz-Moreno, S Palomeras, K Pedersen, B Morancho, T Pascual, ... Breast Cancer Research 23, 1-18, 2021 | 14 | 2021 |
Nicotinamide N‐methyltransferase sustains a core epigenetic program that promotes metastatic colonization in breast cancer JP Couto, M Vulin, C Jehanno, MM Coissieux, B Hamelin, A Schmidt, ... The EMBO journal 42 (13), e112559, 2023 | 5 | 2023 |
RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer M Ciscar, EM Trinidad, G Perez‐Chacon, M Alsaleem, M Jimenez, ... EMBO Molecular Medicine 15 (4), e16715, 2023 | 1 | 2023 |
RANK is an independent biomarker of poor prognosis in estrogen receptor-negative breast cancer and a therapeutic target in patient-derived xenografts M Ciscar, EM Trinidad, H Perez-Montoyo, M Alsaleem, ... bioRxiv, 2021.12. 13.470911, 2021 | 1 | 2021 |
RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer S Palomeras, K Pedersen, B Morancho, T Pascual, J Gomez-Miragaya, ... Breast Cancer Research 23 (1), 2021 | | 2021 |
Identification of mechanisms of acquired resistance to taxanes in triple negative breast cancer using patient-derived xenografts: a step closer to clinics J Gómez Miragaya Universitat de Barcelona, 2018 | | 2018 |
Therapeutic opportunities of RANK pathway in breast cancer H Perez Montoyo, J Gomez Miragaya, EM Trinidad, A Martinez-Aranda, ... Cancer Research 76 (14_Supplement), 4389-4389, 2016 | | 2016 |
Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity against Breast Cancer Models Resistant to Anti-HER2 Drugs A Giro-Perafita, G Oliveras Serrat, S Palomeras, C Turrado, ... PLoS One, 2015, vol. 10, num. 6, p. e0131241, 2015 | | 2015 |